Canada markets closed
  • S&P/TSX

    19,501.49
    +41.57 (+0.21%)
     
  • S&P 500

    3,970.99
    +22.27 (+0.56%)
     
  • DOW

    32,237.53
    +132.28 (+0.41%)
     
  • CAD/USD

    0.7277
    -0.0020 (-0.27%)
     
  • CRUDE OIL

    69.20
    -0.76 (-1.09%)
     
  • Bitcoin CAD

    38,027.55
    -1,009.92 (-2.59%)
     
  • CMC Crypto 200

    597.33
    -21.06 (-3.41%)
     
  • GOLD FUTURES

    1,981.00
    -14.90 (-0.75%)
     
  • RUSSELL 2000

    1,734.92
    +14.63 (+0.85%)
     
  • 10-Yr Bond

    3.3800
    -0.0260 (-0.76%)
     
  • NASDAQ

    11,823.96
    +36.56 (+0.31%)
     
  • VOLATILITY

    21.74
    -0.87 (-3.85%)
     
  • FTSE

    7,405.45
    -94.15 (-1.26%)
     
  • NIKKEI 225

    27,385.25
    -34.36 (-0.13%)
     
  • CAD/EUR

    0.6759
    +0.0029 (+0.43%)
     

Stocks in play: PharmaTher Inc

Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing KETARX™ into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease. This Type C meeting allows the Company to discuss with the FDA its plans for a Phase 3 clinical study to support the submission of a new drug application under the 505(b)(2) regulatory pathway for KETARX™ in treating LID-PD. In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™. The Type C meeting is via written responses. The goal date for the FDA in providing its written responses is March 20, 2023. PharmaTher Inc shares C.PHRM are trading unchanged at $0.12.

Read: